GlassScriptPhysician profile
Jacklyn D Eyre
NPI 1336487198
$9,238.25
in general payments reported to CMS, 2019-2025
34 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,771 · 2022: $1,539 · 2023: $2,258 · 2024: $1,852 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,926 · Education: $2.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,925.89 |
| Education | $2.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,706.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,243.52 | 2021-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $1,232.77 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,199.52 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $555.93 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $471.15 | 2021-2025 | |
| Pfizer INC. | $312.23 | 2021-2025 | |
| Esperion Therapeutics, INC. | $293.46 | 2021-2024 | Nexletol |
| Glaxosmithkline, LLC. | $288.23 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.60 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $195.77 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $186.51 | 2024 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $146.25 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $134.23 | 2022 | |
| Sumitomo Pharma America, INC. | $107.43 | 2023-2025 | Gemtesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $105.27 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.49 | 2022-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $78.30 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $74.06 | 2021-2022 | |
| Cranial Technologies, INC | $71.67 | 2021-2025 | Doc Band |
| Biohaven Pharmaceuticals, INC. | $69.90 | 2021 | |
| Merck Sharp & Dohme LLC | $57.88 | 2021-2024 | Gardasil 9, Gardasil |
| Abbott Laboratories | $50.10 | 2023-2024 | Freestyle Libre 3 |
| Seqirus USA INC | $48.10 | 2024-2025 | Flucelvax, Fluad |
| Boston Scientific Corporation | $43.26 | 2024 | |
| Exact Sciences Corporation | $31.05 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Medicure Pharma INC. | $27.54 | 2021 | |
| Lucid Diagnostics INC. | $26.42 | 2022 | |
| Biogen, INC. | $24.75 | 2025 | Spinraza |
| Nevro Corp. | $24.38 | 2023 | Senza |
| Edwards Lifesciences Corporation | $21.97 | 2023 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $20.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.30 | 2023 | Xarelto |
| Arbor Pharmaceuticals, INC. | $15.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacklyn Eyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.